Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding.
Key facts
- Where
- Hellerup, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
Source: NCT07893743, who can take part
Where in Denmark
- Center for Clinical Metabolic Research, Gentofte HospitalHellerup, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Gentofte, Copenhagen
- Trial code
- NCT07893743
- Record updated
- 26 October 2026
- Original description
The purpose of this study is to investigate whether lifestyle factors can alter gut barrier integrity and whether disruptions of the gut barrier can trigger systemic and tissue-specific inflammation. Twenty participants will undergo 14 days of fast-food overfeeding. Gut barrier function will be assessed before and after the intervention, alongside a wide palette of imaging techniques and biological analyses to characterize inflammatory status.Read full original descriptionShow less
The purpose of this study is to investigate whether lifestyle factors can alter gut barrier integrity and whether disruptions of the gut barrier can trigger systemic and tissue-specific inflammation. Twenty participants will undergo 14 days of fast-food overfeeding. Gut barrier function will be assessed before and after the intervention, alongside a wide palette of imaging techniques and biological analyses to characterize inflammatory status.
Inclusion: Normal fasting plasma glucose and glycated hemoglobin (HbA1c) <42 mmol/mol; Body mass index (BMI) between 18.5 and 25 kg/m2; Hemoglobin >8.3 mmol/l; Participants must consume a ordinary mixed diet and not follow restrictive or specialized dietary regimens; Age between 20 and 40 years; Oral and written informed consent.
Exclusion: Regular use of prescription medication or treatment with systemic antibiotics less than three weeks before the screening visit; Use of over-the-counter medication or any dietary supplements known to alter gastrointestinal function, including probiotics, for the period of the study and three weeks prior to screening; Diabetes; Known gastrointestinal disease, major or recent abdominal surgery; First degree relatives with inflammatory bowel disease; History of BMI > 30; Current or history of psychiatric eating disorder; Physical or mental conditions incompatible with magnetic resonance scanning modalities, including implanted metal objects; Any condition that the investigator feels would interfere with study completion; Fasting plasma triacylglycerol indicating dyslipidemia (≥2 mmol/l); Nephropathy (estimated glomerular filtration rate (eGFR) <60 ml/min and/or albuminuria with an albumin to creatinine ratio of >30 μg/mg); Known liver disease and/or alanine aminotransferase (ALT) >2 × upper reference limits; Regular use of nicotine products in any form; Regular alcohol intake above 18 units per week; Signs of liver fibrosis and/or steatosis evaluated by FibroScan (CAP value >238 dB/m and/or kPa >5.0) and/or FIB-4 score (>1.45); More than two weekly strength and/or aerobic training sessions on a regular basis; Not willing to agree to use effective contraception during and for 90 days after end of the diet intervention. Acceptable contraception includes condom use and/or ensuring that the female partner(s) uses highly effective contraception.